2021 Targeted Therapies of Lung Cancer (TTLC) Meeting - Posters-P09. Mutated EGFR Pulmonary Adenocarcinoma Experience of the Medical Oncology Department of the Hassan II Hospital University in Fez

P09. Mutated EGFR Pulmonary Adenocarcinoma Experience of the Medical Oncology Department of the Hassan II Hospital University in Fez - PDF

Back to course

Pdf Summary

This study conducted by the Medical Oncology Department of Hassan II Hospital University in Fez, Morocco, aimed to describe the epidemiological, clinical, and evolutionary aspects of EGFR (Epidermal Growth Factor Receptor) mutated pulmonary adenocarcinoma. The study included 140 cases of pulmonary adenocarcinoma collected over a period of thirty months from October 2017 to April 2020. The mean age at diagnosis was 60.18 years, with a higher prevalence in males. Smoking was identified as the main risk factor. The most common clinical symptoms included chest pain, cough, and dyspnea. The right upper lobe was the most commonly affected site. Over half of the patients presented with metastases, with the most common sites being the lungs, bones, liver, brain, and adrenal glands. Among the patients, 22% were found to have EGFR mutations, with a slightly higher proportion in females. Smoking status was almost evenly distributed between smokers and non-smokers. The most frequent mutations were found in exons 19, 20, 21, and 18. The majority of patients without EGFR mutations received chemotherapy, with a progression-free survival of approximately 9.6%. Fourteen patients received anti-EGFR TKI (Tyrosine Kinase Inhibitor) as a first-line therapy, with a progression-free survival of around 15.7 months. Seventeen patients received platinum and taxane chemotherapy, with a progression-free survival of 12.3 months. The study concludes that TKI has revolutionized the prognosis of EGFR mutated adenocarcinoma, emphasizing the importance of generalized treatment for all eligible patients.

Asset Subtitle

Yassine El Ouai

Meta Tag

Speaker Yassine El Ouai

Topic Targeted Therapies - EGFR

Keywords

EGFR mutated pulmonary adenocarcinoma

epidemiological

clinical

evolutionary aspects

pulmonary adenocarcinoma

smoking

metastases

EGFR mutations

chemotherapy

TKI treatment